Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

APRI 1.30 -0.01 (-0.76%)
price chart
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences Announces Corporate Update and Third Quarter 2014 ...
Apricus Biosciences, Inc. APRI, +2.31% a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the Company's third quarter financial results will be released on Monday, November 10, 2014.
Related articles »  
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...
SAN DIEGO, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced the launch of Vytaros� in Belgium by the Sandoz ...
Related articles »  
Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application ...
SAN DIEGO, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the United States Patent and Trademark Office ...
Related articles »  
Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that Richard Pascoe, Chief Executive Officer, will ...
Related articles »  
Apricus Biosciences to Present at Three Upcoming Investor Conferences in ...
SAN DIEGO, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members of senior management will present at the ...
Related articles »  
Apricus Biosciences Announces Third Quarter 2014 Financial Results and ...
10, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today provided a corporate update and reported financial results for the third quarter ...
Apricus Biosciences (APRI) Posts Quarterly Earnings, Beats Expectations By ...  WKRB News
Related articles »  
Apricus Biosciences, Inc. (APRI) � Developing Novel Health Solutions
October 3, 2014 (Investorideas.com Newswire) San Diego-based Apricus Biosciences is finding solutions for unmet medical needs.
Apricus Biosciences Inc (APRI) news: 2014 Could Be A Transformative Year For ...
Apricus Biosciences, Inc. (NASDAQ:APRI) is a pharmaceutical company that develops and markets treatments for male and female sexual health.
Related articles »  
Apricus Biosciences Enters Into Common Stock Purchase Agreement With ...
SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI) (the "Company" or "Apricus"), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced it has entered into a ...
Apricus Biosciences' (APRI) CEO Richard Pascoe on Q2 2014 Results ...  Seeking Alpha (registration)
Related articles »